Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based Basilea Pharmaceutica has submitted a marketing authorization application for Toctino in 13 additional EU member states as well as in Norway and Iceland.
Subscribe to our email newsletter
Toctino is a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids.
The marketing authorization application (MAA) for Toctino was submitted under the repeat use procedure to various EU member states and European countries.
Anthony Man, CEO of Basilea Pharmaceutica, said: “It is important for us to make Toctino available across Europe for physicians to treat patients with this chronic debilitating disease. Our submission in 15 additional European countries is a key step towards this goal. Furthermore, pending local approval of this second wave of MAAs, we are exploring options for third-party distribution of this innovative medicine in some of these countries.”